Provided by Tiger Trade Technology Pte. Ltd.

RenovoRx Inc

1.42
+0.170013.60%
Post-market: 1.40-0.0200-1.41%16:05 EDT
Volume:1.27M
Turnover:1.84M
Market Cap:63.97M
PE:-4.59
High:1.56
Open:1.30
Low:1.27
Close:1.25
52wk High:1.56
52wk Low:0.7006
Shares:45.05M
Float Shares:39.17M
Volume Ratio:3.24
T/O Rate:3.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3096
EPS(LYR):-0.3161
ROE:-125.23%
ROA:-64.90%
PB:7.12
PE(LYR):-4.49

Loading ...

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

THOMSON REUTERS
·
May 28

RenovoRx announces pharmacokinetic data using TAMP platform

TIPRANKS
·
May 26

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

GlobeNewswire
·
May 26

RenovoRx releases investor presentation outlining RenovoCath commercialization ramp and TAMP platform for targeted cancer drug delivery

Reuters
·
May 24

RenovoRx Insider Makes Bold Move With Fresh Share Purchase

TIPRANKS
·
May 22

RenovoRx CFO Mark Voll buys 25,000 shares valued at $19,690

Reuters
·
May 21

RenovoRx Earnings Call Signals Commercial Inflection

TIPRANKS
·
May 20

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

GlobeNewswire
·
May 19

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) and RenovoRx (RNXT)

TIPRANKS
·
May 16

RenovoRx (RNXT) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 15

RenovoRx Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)

TIPRANKS
·
May 15

RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M

TIPRANKS
·
May 15

RenovoRx Q1 net loss widens 45% to $3.52 million; revenue rises 186% to $563,000

Reuters
·
May 15

RenovoRx Q1 revenue rises as number of active cancer centers increase

Reuters
·
May 15

RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.

Benzinga Earnings
·
May 15

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-Over-Quarter

THOMSON REUTERS
·
May 15

RenovoRx Q1 Revenue $563,000

THOMSON REUTERS
·
May 15

RenovoRx Q1 Adjusted EPS USD -0.08 VS. Ibes Estimate USD -0.08

THOMSON REUTERS
·
May 15

RENOVORX REITERATES FULL YEAR 2026 REVENUE GUIDANCE OF $3 MLN - $4 MLN\n

THOMSON REUTERS
·
May 15